COMPLETED

Cerebrospinal Fluid Biomarkers in Bariatric Surgery

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this project is to understand why bariatric surgery is such an effective treatment for obesity with a focus on brain mechanisms. Cerebrospinal fluid (CSF) neuropeptide, hormone and protein levels will be measured as a surrogate for changes in brain activity in participants before and after bariatric surgery as compared with participants before and after diet-induced weight loss. The investigators are studying neuropeptides and hormones that are know to be involved with the regulation of appetite and body weight to determine if some of the changes that are expected to occur after diet-induced weight loss do not occur after bariatric surgery. In addition, proteomic analysis will be used to uncover new protein biomarkers that are unique to surgical weight loss. The results of these studies will help explain why bariatric surgery is so effective in achieving long-term weight loss. Understanding how the central nervous system responds to bariatric surgery could help the development of alternative nonsurgical therapies for obesity and its metabolic complications.

Official Title

Changes in Cerebrospinal Fluid Biomarkers After Bariatric Surgery

Quick Facts

Study Start:2020-10-20
Study Completion:2025-12-29
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:COMPLETED

Study ID

NCT04350892

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 65 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * 18-65 years old
  2. * BMI 35-55
  1. * No clinically significant medical conditions
  2. * No use of tobacco
  3. * No alcohol or drug abuse
  4. * No recent weight change (+/-5%) within prior 6 months
  5. * No medications that may affect body weight or blood glucose
  6. * No diabetes medications, beta-blockers, opiates or glucocorticoids
  7. * No pregnancy, breastfeeding, or planning to become pregnant during the study (diet group only)
  8. * No lactose intolerance

Contacts and Locations

Principal Investigator

Sharon L Wardlaw, MD
PRINCIPAL_INVESTIGATOR
Columbia University

Study Locations (Sites)

Columbia University Medical Center
New York, New York, 10032
United States

Collaborators and Investigators

Sponsor: Columbia University

  • Sharon L Wardlaw, MD, PRINCIPAL_INVESTIGATOR, Columbia University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-10-20
Study Completion Date2025-12-29

Study Record Updates

Study Start Date2020-10-20
Study Completion Date2025-12-29

Terms related to this study

Keywords Provided by Researchers

  • Obesity
  • Bariatric Surgery
  • Gastric Bypass
  • Sleeve Gastrectomy
  • Weight Loss
  • Low Calorie Diet

Additional Relevant MeSH Terms

  • Obesity